Markus F. Scheerer

1.8k total citations · 1 hit paper
38 papers, 753 citations indexed

About

Markus F. Scheerer is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Markus F. Scheerer has authored 38 papers receiving a total of 753 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Surgery and 13 papers in Molecular Biology. Recurrent topics in Markus F. Scheerer's work include Diabetes Treatment and Management (22 papers), Pancreatic function and diabetes (14 papers) and Diabetes Management and Research (13 papers). Markus F. Scheerer is often cited by papers focused on Diabetes Treatment and Management (22 papers), Pancreatic function and diabetes (14 papers) and Diabetes Management and Research (13 papers). Markus F. Scheerer collaborates with scholars based in Germany, United States and United Kingdom. Markus F. Scheerer's co-authors include Moshe Phillip, Peter Rossing, Chantal Mathieu, Fredrik Thorén, Paresh Dandona, Luís M. Ruilope, Charlie Scott, Bertram Pitt, Stefan D. Anker and George L. Bakris and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Markus F. Scheerer

34 papers receiving 741 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

2025 44 citations Rajiv Agarwal, Jennifer B. Green et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Markus F. Scheerer Germany	19	543	290	197	119	110	38	753
Aliza Rozenberg Israel	13	663 1.2×	266 0.9×	206 1.0×	59 0.5×	64 0.6×	26	753
Ilan Yanuv Israel	13	663 1.2×	265 0.9×	206 1.0×	59 0.5×	64 0.6×	25	751
Maria Leonsson‐Zachrisson Sweden	14	587 1.1×	324 1.1×	206 1.0×	209 1.8×	89 0.8×	21	1.0k
Ling Ge United States	11	483 0.9×	110 0.4×	192 1.0×	190 1.6×	93 0.8×	24	798
Минара Шамхаловна Шамхалова Russia	11	353 0.7×	172 0.6×	191 1.0×	85 0.7×	44 0.4×	86	618
Claire C. J. Dekkers Netherlands	9	599 1.1×	319 1.1×	210 1.1×	92 0.8×	132 1.2×	13	734
Smail Messaoudi France	12	339 0.6×	204 0.7×	182 0.9×	155 1.3×	70 0.6×	12	519
Zin Zin Htike United Kingdom	10	804 1.5×	283 1.0×	365 1.9×	102 0.9×	62 0.6×	14	924
Michaël J.B. van Baar Netherlands	7	656 1.2×	311 1.1×	233 1.2×	67 0.6×	88 0.8×	12	773
Norm Rosenthal United States	9	623 1.1×	285 1.0×	364 1.8×	57 0.5×	87 0.8×	19	778

Countries citing papers authored by Markus F. Scheerer

Since Specialization

Citations

This map shows the geographic impact of Markus F. Scheerer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus F. Scheerer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus F. Scheerer more than expected).

Fields of papers citing papers by Markus F. Scheerer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus F. Scheerer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus F. Scheerer. The network helps show where Markus F. Scheerer may publish in the future.

Co-authorship network of co-authors of Markus F. Scheerer

This figure shows the co-authorship network connecting the top 25 collaborators of Markus F. Scheerer. A scholar is included among the top collaborators of Markus F. Scheerer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus F. Scheerer. Markus F. Scheerer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heerspink, Hiddo J.L., Niels Jongs, Chantal Mathieu, et al.. (2026). Finerenone in Type 1 Diabetes and Chronic Kidney Disease. New England Journal of Medicine. 394(10). 947–957.

Ostrominski, John W., Finnian R. Mc Causland, Brian Claggett, et al.. (2025). Finerenone Across the Spectrum of Kidney Risk in Heart Failure. JACC Heart Failure. 14(1). 102439–102439. 3 indexed citations

Ostrominski, John W., Brian Claggett, Akshay S. Desai, et al.. (2025). EFFICACY AND SAFETY OF FINERENONE ACROSS THE SPECTRUM OF KIDNEY RISK IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION. Journal of the American College of Cardiology. 85(12). 1167–1167.

Desai, Akshay S., Pardeep S. Jhund, Muthiah Vaduganathan, et al.. (2025). Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology. 10(7). 678–678. 1 indexed citations

Butt, Jawad H., Alasdair Henderson, Pardeep S. Jhund, et al.. (2025). FINERENONE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION: AN ANALYSIS OF FINEARTS-HF. Journal of the American College of Cardiology. 85(12). 1200–1200.

Butt, Jawad H., Pardeep S. Jhund, Alasdair Henderson, et al.. (2025). Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure. 27(8). 1444–1458. 1 indexed citations

Lu, Henri, Brian Claggett, Muthiah Vaduganathan, et al.. (2025). Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Failure. 13(10). 102590–102590.

Agarwal, Rajiv, Jennifer B. Green, Hiddo J.L. Heerspink, et al.. (2025). Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 393(6). 533–543. 44 indexed citations breakdown →

Vaduganathan, Muthiah, Brian Claggett, Ian J. Kulac, et al.. (2024). Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 151(2). 149–158. 25 indexed citations

10.

Causland, Finnian R. Mc, Muthiah Vaduganathan, Brian Claggett, et al.. (2024). Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations

11.

Causland, Finnian R. Mc, Muthiah Vaduganathan, Brian Claggett, et al.. (2024). Finerenone and Kidney Outcomes in Patients With Heart Failure. Journal of the American College of Cardiology. 85(2). 159–168. 21 indexed citations

12.

Heerspink, Hiddo J.L., Andreas L. Birkenfeld, David Z.I. Cherney, et al.. (2023). Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Research and Clinical Practice. 204. 110908–110908. 27 indexed citations

13.

Ruilope, Luís M., Bertram Pitt, Stefan D. Anker, et al.. (2022). Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrology Dialysis Transplantation. 38(2). 372–383. 39 indexed citations

14.

Rossing, Peter, Gerasimos Filippatos, Rajiv Agarwal, et al.. (2021). Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney International Reports. 7(1). 36–45. 101 indexed citations

15.

Rossing, Peter, Gerasimos Filippatos, George L. Bakris, et al.. (2021). Finerenone in Patients with CKD and Type 2 Diabetes by SGLT-2i Treatment: The FIDELITY Analysis. Journal of the American Society of Nephrology. 32(10S). 45–45. 3 indexed citations

16.

Huang, Jialing, Cornelia Huth, Marcela Covic, et al.. (2020). Machine Learning Approaches Reveal Metabolic Signatures of Incident Chronic Kidney Disease in Individuals With Prediabetes and Type 2 Diabetes. Diabetes. 69(12). 2756–2765. 39 indexed citations

17.

Groop, Per‐Henrik, Paresh Dandona, Moshe Phillip, et al.. (2020). Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. The Lancet Diabetes & Endocrinology. 8(10). 845–854. 53 indexed citations

18.

Aberle, Jens, Sebastian Schmid, Christoph Terkamp, et al.. (2020). Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes. Scientific Reports. 10(1). 22396–22396. 33 indexed citations

19.

Busse, David, Weifeng Tang, Markus F. Scheerer, et al.. (2019). Comparison of pharmacokinetics and the exposure–response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus. British Journal of Clinical Pharmacology. 85(8). 1820–1828. 11 indexed citations

20.

Scheerer, Markus F., et al.. (2016). Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes Metabolic Syndrome and Obesity. Volume 9. 337–345. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact